FI94865C - Process for the preparation of pharmaceutically acceptable (7,17) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -en-20-yn-3-one in crystalline pure form - Google Patents

Abstract

A pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7 alpha ,17 alpha )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, characterized in that the said compound is crystalline pure and completely or virtually completely free from the other crystalline form.

Description

1 94865

The invention relates to a process for the preparation of a pharmaceutically acceptable (7a, 17a) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -en-20-yn-3-one in crystalline pure form. 17a) to prepare a pure crystalline form of -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -en-20-yn-3-one.

Compound (7a, 17a) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -en-20-yn-3-one of structural formula 110

OH

^ jJUcECH

XJkJ ·· CHj 15 is known, for example, from U.S. Patent 3,340,279 and U.S. Patent 4,701,450. The method described in these patents results in a compound having combined estrogenic, progestagenic and androgenic properties. This compound is used in drugs having gonadomimetic, ovulation inhibitory or resistance modulating activity.

It has now surprisingly been found that a compound of formula 1 prepared in the above-mentioned patents • · ♦. 25 is polymorphic and consists of two crystalline, pure forms.

The biological activity of the polymorphic compounds can be expected to be comparable or identical to the biological activities of the crystalline, pure forms of which the polymorphic compound is composed. However, if the polymorphic compound is used as a drug, there are significant disadvantages associated with its use compared to the use of its crystalline, pure forms. Differences in crystal structure can lead to differences in physicochemical parameters such as stability, dissolution rate, melting point, analytical data, and the like, which are often strongly influenced by the crystal structures of the polymorphic compound. All of this is becoming increasingly apparent because it is virtually impossible to make each batch of a polymorphic compound completely identical in composition. As a result of these differences, the inclusion of polymorphic compounds in drugs is often not considered desirable and it is sometimes required that only one crystalline, pure component of the polymorphic compound be used.

It is therefore an object of the present invention to provide a crystalline pure form of a compound of formula 1 for use in a pharmaceutical composition which is completely or substantially completely free of another crystalline form.

The term "crystalline pure form which is substantially completely free of the second crystalline form" means a form containing less than 10% and preferably less than 5% of the second crystalline form.

It has now been found that using specific crystallization techniques, polymorphic compound 1 can be obtained in two crystalline, pure forms, which are referred to herein as Form I and Form II, respectively.

In addition, it has been found that Form I is chemically> ·: ·. 25 more stable than the already known polymorphic compound 1. This improvement in stability leads to significant advantages in the shelf life of the Form I-containing pharmaceutical product.

Accordingly, the invention relates to a process for the preparation of pharmaceutically acceptable (7α, 17α) -17-hydroxy-7-methyl-19 - [? - ** - nor-17-pregn-5 (10) -en-20-yn-3 to be crystalline in pure form I, which is completely or practically completely free of the second crystalline form.

The pharmaceutical composition containing Form I has the advantage that the reproducibility of its preparation is improved and that the physical data are always identical within acceptable limits.

The pure crystalline compound of form I is suitable for the treatment of menopause or for modulating the immune system, as well as for the prevention and treatment of osteoporosis.

According to the invention, Form I is obtained by crystallization of polymorphic compound 1 from a selected polar solvent. A suitable procedure is a polymorphic compound in acetone or ethanol, after which this solution is added to water. On the other hand, water can also be added to an acetone or ethanol solution of the polymorphic compound. Other suitable solvents include, for example, ethyl acetate, acetonitrile and acetone / hexane mixtures. Mixtures of methanol and water, of which only mixtures of the two crystalline forms always crystallize, are not suitable.

Form II, the preparation of which is not covered by the claims, can be obtained by crystallizing the polymorphic compound from a selection of non-polar solvents, for example toluene or hexane to which a little ethyl acetate has been added. Trichlorethylene is also a suitable solvent.

The rate of crystallization, which is most strongly influenced by the crystallization temperature, can also have an effect on obtaining crystalline, pure forms. Thus anhydrous ·. 25 acetone generally gives good results only when crystallization is performed at a relatively low temperature.

Forms I and II can be easily distinguished from each other. Three methods are particularly suitable, i. powder X-ray diffraction, infrared techniques and solid state 13 C-NMR spectroscopy.

Powder X-ray diffraction spectra are given in Figures 1, 2 and 3. Figure 1 shows the Form I spectrum, while Figure 2 shows the Form II spectrum. The differences are obviously 35. The Double Peaks obtained for Form I are characteristic of it.

4,94865

Figure 3 shows the spectrum of polymorphic compound 1, which clearly differs from the spectra of Forms I and II.

The Fourier transform scattered infrared (DRIFT) spectra of Forms I and II are shown in Figure 4. Here, the clear differences between the two forms are also asserted here, the notable Form I Double peaks between 3,000 and 3,700 cm * 1.

The solid state, 3 C-NMR spectra of Forms I and II are given in Figures 5 and 6, respectively. The differences are evident and in the case of Form I the duplication of the peaks is again remarkable.

These three techniques are particularly well suited for determining the amount of Form II in Pure Form I and the amount of Form I in Pure Form II. In the case of the powder X-ray diffraction technique, the two strongest peaks (13.7 and 17.4 degrees for Form I, Figure 1; 13.5 and 17.4 degrees for Form II, Figure II) are compared, after which the amount of each form can be calculated using a calibration curve.

By DRIFT spectroscopy, the OH stretching frequencies, which give a single absorption line in the case of Form II and a double absorption line in the case of Form I, can be compared and the concentration again determined by means of a calibration curve.

• «: ·. Concentration can be determined very accurately by solid state 13 C-NMR spectroscopy with peak integration.

To prepare a pharmaceutical composition, the crystalline pure form is mixed with a suitable pharmaceutical carrier and administered parenterally or orally, for example as a suspension, ointment, solution or emulsion, or in a solid pharmaceutically acceptable form such as a tablet, pill, capsule or suppository.

35 Dosage regimens are similar to those described in the above patents. A daily dose of 1 to 5 mg orally is particularly suitable for human administration.

il lU.l llll IM U. .

94865 5

With a pharmaceutical composition which - contains crystalline pure Form I, much better stability is achieved, whereby the storage time is considerably extended even if the storage conditions change.

The invention is illustrated by the following examples.

Example 1 4.0 g of the polymorphic compound (7a, 17a) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -en-20-yn-3-one was recrystallized in the presence of nitrogen. 20 ml of acetone to which a little pyridine had been added. During the procedure, the temperature was slowly lowered from room temperature to -10 ° C. The crystals were filtered off from the solution and washed with acetone at -20 ° C and dried under reduced pressure at 40-45 ° C.

The yield was 3.0 g of Form I (purity according to DRIFT 94% calculated from 3,410 cm -1 '/ 3,490 cm -1), m.p. 165-170 ° C.

Example 2 1 kg of polymorphic compound 1 was dissolved at 20-25 ° C in a mixture of 23 l of acetone and 6 ml of pyridine. The solution was filtered free of particles and the filter was washed twice with 1 L of acetone. At a temperature of 15 to 20 ° C, the filtrate was poured as quickly as possible, in the presence of nitrogen, into 25 l of particle-free distilled water, I 'i *. 25 to which Form I crystal elements had been added. The suspension was cooled to 0-5 ° C and stirred at this temperature for one hour. The crystals were filtered off from the solution, washed with particle-free distilled water and dried under reduced pressure at 40 ° C. The yield was 0.95 kg of Form 30 L (purity according to DRIFT 97.2%).

»·

Example 3

In a manner comparable to Example 2, four batches of Form I were obtained with 100%, 95.2%, 93.3% and 99.2% purity, respectively (all determined by DRIFT).

6,94865

Example 4 2.3 kg of polymorphic compound 1 was dissolved in a mixture of 63 l of 96% ethanol and 114 ml of pyridine. This mixture was then poured as quickly as possible, while stirring well, into a particle-free solution of 53.5 l of water and 268 ml of pyridine at 18-20 ° C, to which Form I crystals had been added.

The mixture was rinsed with 3 L of ethanol and the mixture was stirred for 15 min at 18-20 ° C. The crystals were filtered off from the solution, washed twice with a mixture of 10 l of particle-free distilled water and 2 ml of pyridine, and then the crystals were washed three times with 18 l of particle-free distilled water at 50 ° C. The crystals were dried under reduced pressure at 40 ° C. The yield was 2.1 kg of Form I (purity according to DRIFT 94.7 15%).

Example 5 (Comparative Example) 5.0 g of polymorphic compound 1 was dissolved at 40 ° C in 50 ml of ethyl acetate to which a little pyridine had been added. At about 35 ° C, 300 mL of hexane was added with vigorous stirring, after which the mixture was cooled to 0 ° C and stirred for an additional 30 min. The crystals were filtered off from the solution and washed with hexane at 0 ° C. The yield was 4.25 g of Form II (purity according to DRIFT 100%).

• 25 Example 6

A tablet was prepared having the following composition: Form I (obtained according to Example 2) 2.5 mg starch 10 mg ascorbyl palmitate 0.2 mg magnesium stearate 0.5 mg lactose to give a total of 100 mg

The granules were prepared by mixing lactose with a portion of starch. The rest of the starch was mixed with 35 water as a suspension and added to the mixture. The whole mixture was granulated and dried. These base granules were mixed with as-corbyl palmitate and Form I, screened, mixed well with magnesium stearate and then tableted.

5 Example 7

A tablet having a composition similar to Example 6 was prepared by first mixing together Form X, 10% lactose and ascorbyl palmitate and then mixing this mixture with lactose, starch and starch lysate suspension. The mixture was dried, mixed well with magnesium stearate and tableted.

Example 8

For Form I and II samples, structural data were determined on an Enraf-Nonius CAD-4 diffractometer using CuKa. The structure was determined by direct methods of SHELXS86. The following information was obtained:

Form I

monoclinic P2j, a = 6.5298, b = 41.205, c = 6.6702 Å, β = 101.526 °, V = 1758 Å3, Z = 4, Dx = 1.180 gem'3, μ = 5 20 cm1, F (000 ) = 680, room temperature, R = 0.060 for 1831 reflection when I> = 2.5σ (Ι). A symmetric unit consists of two independent molecules. The A ring of molecule 1 is 2β, 3α semi-chair-like and the 2 A ring of molecule 2B, 3α is semi-chair-like. The B-rings * 25 of each molecule adopt a 7α, 8B semi-chair-like conformation. Both C-rings are slightly bent chairs and the D-rings have a bent 13B envelope configuration.

Form II

triclinic P1, a = 6.5242, b = 6.6773, c = 10.287 Å, a = 30 87.05, β = 80.09, y = 79.17 °, V = 434.7 Å, Z = 1 , Dx = 1.194 gem'3, μ = 5.1 cm1, F (000) = 170, room temperature, R = 0.066 for 1485 reflection when I> = 2.5σ (Ι). The A-ring has a half-chair-like conformation of 23,3a and the B-ring has a 7a, 8β semi-chair-like conformation, and the C-rings adopt a slightly twisted chair conformation. The D-ring has a distorted 13B envelope configuration.

Claims (2)

8,94865 A process for the preparation of pharmaceutically acceptable (7α, 17α) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -en-20-yn-53-one in crystalline pure form which is completely or practically completely free of the second crystalline form, and whose powder X-ray diffraction spectrum largely corresponds to that shown in Figure 1, characterized in that the polymorphic 10 (7a, 17a) -17-hydroxy-7-methyl-19-nor -17-pregn-5 (10) -en-20-yn-3-one is crystallized from a polar solvent. A patent for the preparation of a pharmaceutical composition comprising (7a, 17a) -17-hydroxy-7-methyl-19-nor-17-pregn- • 5 (10) -en-20-yn-3-one in crystalline form. The form is preferably 20 or more than three crystals in the form of crystals and a powder X-ray diffraction pattern having a color difference in Figure 1 of the spectral spectrum, which results in a polymorph (7a, 17a) -. 17-Hydroxy-7-methyl-19-nor-17-pregn-5 (10) -en-20-yn-3-one is a crystalline solid and a solid.